New HIV vaccine shows unprecedented success in preclinical study

A preclinical HIV vaccine candidate produced unusually strong immune responses using a staged shot sequence.

Researchers tested a dosing strategy designed to guide B-cell maturation through successive vaccinations.

Early results were described as highly successful in preclinical testing.

The approach could point to a new long-term HIV prevention strategy beyond PrEP and antiretroviral therapy.